X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2322) 2322
Publication (152) 152
Book Review (71) 71
Magazine Article (42) 42
Book Chapter (23) 23
Book / eBook (9) 9
Conference Proceeding (6) 6
Dissertation (2) 2
Newspaper Article (2) 2
Data Set (1) 1
Paper (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1498) 1498
osteonecrosis (1089) 1089
index medicus (1021) 1021
female (809) 809
male (737) 737
diphosphonates - adverse effects (626) 626
bone density conservation agents - adverse effects (561) 561
osteonecrosis - chemically induced (545) 545
necrosis (533) 533
bisphosphonates (516) 516
middle aged (488) 488
bones (474) 474
osteoporosis (474) 474
prevention (468) 468
aged (438) 438
risk factors (437) 437
dentistry, oral surgery & medicine (429) 429
dentistry (393) 393
surgery (391) 391
zoledronic acid (375) 375
risk-factors (368) 368
jaw (342) 342
jaw diseases - chemically induced (340) 340
adult (326) 326
osteonecrosis - prevention & control (325) 325
animals (317) 317
orthopedics (309) 309
avascular necrosis (273) 273
diphosphonates - therapeutic use (271) 271
bone (264) 264
cancer (258) 258
bone density conservation agents - therapeutic use (250) 250
therapy (248) 248
diphosphonates - administration & dosage (228) 228
bisphosphonate (227) 227
oncology (221) 221
bone density conservation agents - administration & dosage (213) 213
aged, 80 and over (211) 211
care and treatment (208) 208
osteoporosis - drug therapy (202) 202
treatment outcome (199) 199
osteonecrosis of the jaw (185) 185
retrospective studies (179) 179
health aspects (174) 174
osteonecrosis - etiology (170) 170
alendronate (163) 163
diphosphonates (163) 163
research (161) 161
bisphosphonate-related osteonecrosis (156) 156
denosumab (150) 150
multiple-myeloma (147) 147
femoral-head (145) 145
management (144) 144
medicine & public health (144) 144
phosphonates (139) 139
medicine, general & internal (136) 136
bisphosphonate-associated osteonecrosis of the jaw - etiology (135) 135
abridged index medicus (134) 134
analysis (133) 133
imidazoles - adverse effects (131) 131
patients (131) 131
fractures (130) 130
jaw diseases - prevention & control (129) 129
medicine, research & experimental (126) 126
osteonecrosis - pathology (125) 125
bone neoplasms - drug therapy (124) 124
rats (124) 124
jaws (123) 123
time factors (123) 123
bisphosphonate-associated osteonecrosis of the jaw - prevention & control (121) 121
bone neoplasms - secondary (121) 121
cancer-patients (120) 120
endocrinology & metabolism (119) 119
rheumatology (119) 119
risk (119) 119
adolescent (118) 118
follow-up studies (115) 115
pamidronate (115) 115
bone density conservation agent (113) 113
osteonecrosis - diagnosis (112) 112
osteonecrosis - therapy (108) 108
diagnosis (105) 105
medicine (105) 105
rabbits (104) 104
tooth extraction (104) 104
administration, oral (103) 103
complications and side effects (103) 103
drug therapy (103) 103
radiography (101) 101
disease models, animal (98) 98
apoptosis (95) 95
disease (95) 95
breast-cancer (94) 94
bisphosphonate-associated osteonecrosis (93) 93
in-vitro (93) 93
biocompatibility (92) 92
osteonecrosis - surgery (91) 91
postmenopausal women (91) 91
bone metastases (90) 90
femur (89) 89
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2132) 2132
French (52) 52
Japanese (44) 44
German (40) 40
Spanish (26) 26
Italian (16) 16
Chinese (12) 12
Hungarian (10) 10
Korean (10) 10
Portuguese (7) 7
Polish (6) 6
Dutch (5) 5
Croatian (4) 4
Danish (2) 2
Arabic (1) 1
Czech (1) 1
Hebrew (1) 1
Norwegian (1) 1
Russian (1) 1
Slovak (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 15, pp. 1417 - 1427
Among postmenopausal women with osteoporosis and a high risk of fracture, treatment with the monoclonal antibody romosozumab for 12 months followed by... 
MEDICINE, GENERAL & INTERNAL | METAANALYSIS | BONE-MINERAL DENSITY | VERTEBRAL FRACTURES | DISEASE | AORTA | RANDOMIZED-TRIAL | RISK | STRENGTH | POSTMENOPAUSAL WOMEN | SCLEROSTEOSIS | Humans | Antibodies, Monoclonal - adverse effects | Fractures, Bone - epidemiology | Antibodies, Monoclonal - therapeutic use | Risk | Bone Remodeling - drug effects | Alendronate - therapeutic use | Incidence | Spinal Fractures - prevention & control | Female | Drug Therapy, Combination | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Antibodies, Monoclonal - pharmacology | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Alendronate - adverse effects | Bone Density - drug effects | Alendronate - pharmacology | Least-Squares Analysis | Aged | Cardiovascular Diseases - chemically induced | Fractures, Bone - prevention & control | Treatment outcome | Care and treatment | Fractures | Growth | Analysis | Monoclonal antibodies | Bones | Research | Jaw | Femur | Vertebrae | Immunoglobulins | Inhibitor drugs | Osteonecrosis | SOST protein | Bisphosphonates | Hip | Post-menopause | Bone resorption | Osteoporosis | Alendronic acid | Bone growth | Bone density | Drug therapy | Osteogenesis | randomized-trial | metaanalysis | disease | postmenopausal women | strength | bone-mineral density | Klinisk medicin | vertebral fractures | sclerosteosis | Clinical Medicine | aorta | risk | General & Internal Medicine
Journal Article
The Journal of the American Dental Association, ISSN 0002-8177, 11/2011, Volume 142, Issue 11, pp. 1243 - 1251
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 67, Issue 3, pp. 482 - 491
Abstract Background Patients with high-risk localised prostate cancer (PCa) are at risk of developing bone metastases (BMs). Zoledronic acid (ZA) significantly... 
Urology | Androgen deprivation therapy | Zoledronic acid | Anticancer agents | Bisphosphonates | Prostate cancer | Skeletal-related events | Bone metastases | DELTA T-CELLS | PHASE-3 | OSTEONECROSIS | THERAPY | MEN | UROLOGY & NEPHROLOGY | PLACEBO-CONTROLLED TRIAL | Multivariate Analysis | Humans | Middle Aged | Bone Neoplasms - secondary | Imidazoles - administration & dosage | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Treatment Failure | Aged, 80 and over | Diphosphonates - therapeutic use | Prostatic Neoplasms - blood | Adult | Kallikreins - blood | Imidazoles - therapeutic use | Diphosphonates - adverse effects | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Bone Density Conservation Agents - adverse effects | Drug Administration Schedule | Europe | Imidazoles - adverse effects | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Bone Density Conservation Agents - therapeutic use | Diphosphonates - administration & dosage | Lymphatic Metastasis | Bone Density Conservation Agents - administration & dosage | Chi-Square Distribution | Prostate-Specific Antigen - blood | Administration, Intravenous | Bone Neoplasms - prevention & control | Aged | Care and treatment | Metastasis | Research | Health aspects | Oncology, Experimental | Cancer
Journal Article
Journal of Cranio-Maxillo-Facial Surgery, ISSN 1010-5182, 2016, Volume 44, Issue 10, pp. 1689 - 1693
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2012, Volume 48, Issue 16, pp. 3082 - 3092
Journal Article
Journal Article
Clinical Oral Implants Research, ISSN 0905-7161, 10/2018, Volume 29, Issue S17, pp. 465 - 465
Journal Article